Včasná diagnostika kognitivního deficitu – východisko pro adekvátní léčbu demencí

PhDr. Milena Košťálová, Ph.D.

Neurol. praxi 2018; 19(Suppl.1): 4  

Remember POBAV – a short test of picture naming and their recall aimed for early detection of cognitive impairment

doc. MUDr. Aleš Bartoš, Ph.D.

Neurol. praxi 2018; 19(Suppl.1): 5-10  

The POBAV (PICNIC) test is the original Czech test for the early detection of cognitive disorders. The POBAV (PICNIC) stands for an abbreviationof Czech title Picture naming and their recall. The test consists of two parts. The persons are to name each of the 20 picturesin one word and remember these picture names. Then they are asked to recall and write as many picture names as they can during oneminute. Each part of the test evaluates different cognitive functions. Failure even in one part raises suspicion of cognitive impairmentand should prompt further examination. The advantage of the test is a short duration (4-6 minutes) and a simple administration...

Návod k vyšetřování
Test Pojmenování OBrázků A jejich Vybavení (POBAV)
PÍSEMNÁ ZÁMĚRNÁ VERZE

doc. MUDr. Aleš Bartoš, Ph.D.

Neurol. praxi 2018; 19(Suppl.1): 11-13  

Pokyny k používání testu POBAV

doc. MUDr. Aleš Bartoš, Ph.D.

Neurol. praxi 2018; 19(Suppl.1): 14  

Ginkgo biloba EGb761 extract and its use in psychiatry

doc. MUDr. Roman Jirák, CSc.

Neurol. praxi 2018; 19(Suppl.1): 15-18 | DOI: 10.36290/neu.2018.143  

Ginkgo Biloba extract EGb761 constitutes the mixture of many active substances with different pharmacological activities. Finaleffect is synergistic. Main effects are nootropic, neuroprotective, scavenging of free radicals, hemorrheologic. The outcomes ofmany clinical studies in dementia are ambiguous, but most of them demonstrate mild to medium improvement of cognition andnon-cognitive symptoms of dementia. That is why EGb761 is establisched for the treatment of mild cognitive impairment andmild dementias of Alzheimer´s type, for the treatment of vascular dementias and mixed dementias, also as an add-on therapy toacetylcholinesterase inhibitors and...

Phytopharmacology of standardized Ginkgo biloba leaf extract (EGb 761)

PharmDr. MVDr. Vilma Vranová, Ph.D.

Neurol. praxi 2018; 19(Suppl.1): 19-21 | DOI: 10.36290/neu.2018.144  

In recent years, the standardized EGb 761 extract has been one of the most commonly clinically tested and most frequently prescribedphytopharmaceuticals in Europe, being registered as a medication in 72 countries. There is a multitude of preparations inthe market, ranging from registered medications with a precisely defined composition to products of untraceable manufacturerswith virtually unknown composition. Medications with EGb 761 are primarily intended to treat mild cognitive disorder, mild dementiaof the Alzheimer type, vascular dementias, and mixed dementias. Clinical trials show that the use of standardized Ginkgobiloba extract is safe and...

Přehled systematických souhrnů studií: využití extraktu z Ginkgo biloba v léčbě mírného kognitivního poškození a demence

Hong-Feng Zhang, Li-Bo Huang, Yan-Biao Zhong, Qi-Hui Zhou, Hui-Lin Wang, Guo-Qing Zheng, Yan Lin

Neurol. praxi 2018; 19(Suppl.1): 22-24 | DOI: 10.36290/neu.2018.145